Psoriatic Skin Molecular and Histopathological Profiles Following Treatment With Risankizumab Versus Ustekinumab

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.11.042
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Risankizumab Versus Ustekinumab for Plaque Psoriasis: A Critical Appraisal

British Journal of Dermatology
DermatologyMedicine
2019English

Risankizumab vs. Ustekinumab for Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2019English

Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis

Clinical pharmacology and therapy
2018English

Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology
DermatologyMedicine
2017English

Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Retraction Statement: Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology
DermatologyMedicine
2018English

Comparison of Normal Versus Imiquimod-Induced Psoriatic Skin in Mice for Penetration of Drugs and Nanoparticles

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2018English

Risankizumab for the Treatment of Plaque Psoriasis in Adults

Prescriber
Pharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy